ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Sinovac rabies vaccine

Its studies are mostly in Rabies, led by Sinovac Biotech.

Furthest: phase 3, since Jan 5, 20262 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech21 open or runningphase 3since Jan 5, 2026Jan 5, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 5, 2026First study: phase 3 study in RabiesFirst studyNCT07357545 · 2,040 enrolled · China
  2. Feb 10, 2026Phase 3 study in RabiesNCT07416110 · 912 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Sinovac rabies vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07416110Rabies · China3Active, not recruitingJul 15, 2026912
NCT07357545Rabies · China3CompletedSep 21, 20222,040

How it is read

Names in the registry

  • “Sinovac rabies vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.